Court rules Boston Scientific's products do not infringe Medtronic stent patents

By Lisa Kerner

Erie, Pa., May 26 - Boston Scientific Corp. said the Court of Appeals for the Federal Circuit issued a ruling upholding a trial court's decisions in two patent cases with Medtronic.

The trial court judge had ruled that the company's Taxus Express, Express and NIR stents do not infringe four Medtronic stent patents, according to a company news release.

Medtronic appealed the decisions.

The Court of Appeals agreed that Boston Scientific's products were not within the scope of the Medtronic patents.

Two 2005 rulings in the U.S. District Court in Delaware found that Boston Scientific's Taxus and Express stents do not infringe four Medtronic patents. The court also granted summary judgment of non-infringement in favor of Boston Scientific, finding that the NIR stent does not infringe the Medtronic patents.

Boston Scientific is a medical device company based in Natick, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.